[1]
Bauer KA. Current challenges in the management of hemophilia. The American journal of managed care. 2015 Mar:21(6 Suppl):S112-22
[PubMed PMID: 26168206]
[2]
Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, Tiede A, Kessler CM. Acquired hemophilia A: Updated review of evidence and treatment guidance. American journal of hematology. 2017 Jul:92(7):695-705. doi: 10.1002/ajh.24777. Epub 2017 Jun 5
[PubMed PMID: 28470674]
[3]
Haya S. Prophylactic treatment in hemophilic patients with inhibitors. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2019 Sep:30(1S Suppl 1):S14-S18. doi: 10.1097/MBC.0000000000000823. Epub
[PubMed PMID: 31517711]
[4]
Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia : the official journal of the World Federation of Hemophilia. 2019 Jan:25(1):33-44. doi: 10.1111/hae.13618. Epub 2018 Nov 14
[PubMed PMID: 30427582]
[5]
Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A. Thrombosis and haemostasis. 2020 Oct:120(10):1357-1370. doi: 10.1055/s-0040-1714279. Epub 2020 Jul 27
[PubMed PMID: 32717759]
[6]
Corrigan-Curay J, Stein P. FDA Breakthrough Therapy Designation-Trial Design and More - Commentary. Clinical pharmacology and therapeutics. 2021 Oct:110(4):869-870. doi: 10.1002/cpt.2378. Epub 2021 Aug 14
[PubMed PMID: 34389983]
Level 3 (low-level) evidence
[8]
Barg AA, Avishai E, Budnik I, Levy-Mendelovich S, Barazani TB, Kenet G, Livnat T. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort. Pediatric blood & cancer. 2019 Nov:66(11):e27886. doi: 10.1002/pbc.27886. Epub 2019 Jul 26
[PubMed PMID: 31348595]
[9]
Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017 Dec 7:130(23):2463-2468. doi: 10.1182/blood-2017-08-801662. Epub 2017 Oct 17
[PubMed PMID: 29042366]
[10]
Shima M. [Congenital hemophilia: a new treatment paradigm]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2019:60(6):647-658. doi: 10.11406/rinketsu.60.647. Epub
[PubMed PMID: 31281158]
[11]
Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 Dec 12:134(24):2127-2138. doi: 10.1182/blood.2019001869. Epub
[PubMed PMID: 31697801]
[12]
Shima M, Nogami K, Nagami S, Yoshida S, Yoneyama K, Ishiguro A, Suzuki T, Taki M. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia : the official journal of the World Federation of Hemophilia. 2019 Nov:25(6):979-987. doi: 10.1111/hae.13848. Epub 2019 Sep 12
[PubMed PMID: 31515851]
[13]
Franchini M, Marano G, Pati I, Candura F, Profili S, Veropalumbo E, Masiello F, Catalano L, Piccinini V, Vaglio S, Pupella S, Liumbruno GM. Emicizumab for the treatment of haemophilia A: a narrative review. Blood transfusion = Trasfusione del sangue. 2019 May:17(3):223-228. doi: 10.2450/2019.0026-19. Epub
[PubMed PMID: 31246563]
Level 3 (low-level) evidence
[14]
Blair HA. Emicizumab: A Review in Haemophilia A. Drugs. 2019 Oct:79(15):1697-1707. doi: 10.1007/s40265-019-01200-2. Epub
[PubMed PMID: 31542880]
[15]
Al-Banaa K, Alhillan A, Hawa F, Mahmood R, Zaki A, El Abdallah M, Zimmerman J, Musa F. Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report. The American journal of case reports. 2019 Jul 18:20():1046-1048. doi: 10.12659/AJCR.916783. Epub 2019 Jul 18
[PubMed PMID: 31318850]
Level 3 (low-level) evidence
[16]
Rodriguez-Merchan EC, Valentino LA. Emicizumab: Review of the literature and critical appraisal. Haemophilia : the official journal of the World Federation of Hemophilia. 2019 Jan:25(1):11-20. doi: 10.1111/hae.13641. Epub 2018 Nov 15
[PubMed PMID: 30431213]
[17]
Yoneyama K, Schmitt C, Kotani N, Levy GG, Kasai R, Iida S, Shima M, Kawanishi T. A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. Clinical pharmacokinetics. 2018 Sep:57(9):1123-1134. doi: 10.1007/s40262-017-0616-3. Epub
[PubMed PMID: 29214439]
[19]
Castaman G, Santoro C, Coppola A, Mancuso ME, Santoro RC, Bernardini S, Pugliese FR, Lubrano R, Golato M, Tripodi A, Rocino A, Santagostino E, ad hoc Working Group, Biasoli C, Borchiellini A, Catalano A, Contino L, Coluccia A, Cultrera D, De Cristofaro R, Di Minno G, Fabbri A, Franchini M, Gamba G, Giuffrida AC, Gresele P, Giampaolo A, Hassan HJ, Luciani M, Marchesini E, Marino R, Mazzucconi MG, Molinari AC, Morfini M, Notarangelo LD, Peccarisi L, Peyvandi F, Pollio B, Rivolta GF, Ruggieri MP, Sargentini V, Schiavoni M, Sciacovelli L, Serino ML, Siragusa S, Tagliaferri A, Testa S, Tosetto A, Zampogna S, Zanon E. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood transfusion = Trasfusione del sangue. 2020 Mar:18(2):143-151. doi: 10.2450/2019.0186-19. Epub 2019 Oct 18
[PubMed PMID: 31657709]
[20]
. Emicizumab for haemophilia A. Australian prescriber. 2019 Feb:42(1):42. doi: 10.18773/austprescr.2019.010. Epub 2019 Feb 1
[PubMed PMID: 30765913]
[21]
Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. Journal of thrombosis and haemostasis : JTH. 2019 Sep:17(9):1470-1477. doi: 10.1111/jth.14491. Epub 2019 Jun 17
[PubMed PMID: 31124272]
[22]
Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A. Thrombosis and haemostasis. 2019 Sep:119(9):1384-1393. doi: 10.1055/s-0039-1692427. Epub 2019 Jun 16
[PubMed PMID: 31203578]
[23]
Adamkewicz JI, Kiialainen A, Paz-Priel I. Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays. International journal of laboratory hematology. 2020 Apr:42(2):e71-e75. doi: 10.1111/ijlh.13114. Epub 2019 Oct 31
[PubMed PMID: 31670901]
[24]
Jenkins PV, Bowyer A, Burgess C, Gray E, Kitchen S, Murphy P, Platton S, Riddell A, Chowdary P, Lester W. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia : the official journal of the World Federation of Hemophilia. 2020 Jan:26(1):151-155. doi: 10.1111/hae.13903. Epub 2019 Dec 20
[PubMed PMID: 31859415]
[25]
Nogami K, Soeda T, Matsumoto T, Kawabe Y, Kitazawa T, Shima M. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. Journal of thrombosis and haemostasis : JTH. 2018 Jul:16(7):1383-1390. doi: 10.1111/jth.14135. Epub 2018 May 27
[PubMed PMID: 29734520]
[26]
Adamkewicz JI, Chen DC, Paz-Priel I. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays. Thrombosis and haemostasis. 2019 Jul:119(7):1084-1093. doi: 10.1055/s-0039-1688687. Epub 2019 May 7
[PubMed PMID: 31064025]
[27]
Wyrwich KW, Krishnan S, Poon JL, Auguste P, von Maltzahn R, Yu R, von Mackensen S. Interpreting important health-related quality of life change using the Haem-A-QoL. Haemophilia : the official journal of the World Federation of Hemophilia. 2015 Sep:21(5):578-84. doi: 10.1111/hae.12642. Epub 2015 Mar 31
[PubMed PMID: 25828456]
Level 2 (mid-level) evidence
[28]
Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni MV, Windyga J, Llinás A, Goddard NJ, Mohan R, Poonnoose PM, Feldman BM, Lewis SZ, van den Berg HM, Pierce GF, WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia : the official journal of the World Federation of Hemophilia. 2020 Aug:26 Suppl 6():1-158. doi: 10.1111/hae.14046. Epub 2020 Aug 3
[PubMed PMID: 32744769]
[29]
Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jiménez-Yuste V. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. The Lancet. Haematology. 2019 Jun:6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16
[PubMed PMID: 31003963]
Level 2 (mid-level) evidence
[30]
Valentino LA, Baker JR, Butler R, Escobar M, Frick N, Karp S, Koulianos K, Lattimore S, Nugent D, Pugliese JN, Recht M, Reding MT, Rice M, Thibodeaux CB, Skinner M. Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders. Journal of blood medicine. 2021:12():897-911. doi: 10.2147/JBM.S325031. Epub 2021 Oct 21
[PubMed PMID: 34707421]